The Epstein–Barr virus (EBV) protease (PR), coded by the BVRF2 gene, is essential for the maturation of the viral capsid and viral DNA packaging during the late stage of the EBV lytic cycle. Like the other herpesvirus serine PRs, EBV PR could be a target for the inhibition of EBV replication. To date, no data have been reported on the inhibition of EBV PR messenger RNA (mRNA) by small interfering RNA (siRNA).
Methods
In this study, siRNAs targeting EBV PR were delivered to the epithelial 293 cell line stably transfected with the complete B95-8 EBV episome. EBV DNA and PR mRNA were quantified by real-time PCR in cells and supernatant, protein expression was assessed by immunoblotting, and production of EBV infectious particles in the culture medium was measured by Raji cell superinfection.
Results
The EBV PR mRNA within the cells was reduced by 73%, the PR protein by 35% and the amount of virus in the cell supernatant was drastically decreased by 86% or 95%, depending on the method.
Conclusions
The strong effect of the siRNA targeting EBV PR on EBV replication attests to the crucial role played by EBV PR in the production of infectious particles and suggests that targeting this enzyme can be a new strategy against EBV-associated diseases where virus replication occurs.
References
1.
ZimberU., AdldingerH.K., LenoirG.M.Geographical prevalence of two types of Epstein–Barr virus.Virology1986; 154: 56–66.
RickinsonA.B.Epstein–Barr virus. In KnipeD.M., HowleyP.M. (Editors). Fields virology.4th ed.Philadelphia: Lippincott Williams Wilkins2001; pp. 2575–2627.
4.
Thorley-LawsonD.A., DucaK.A., ShapiroM.Epstein–Barr virus: a paradigm for persistent infection – for real and in virtual reality.Trends Immunol2008; 29: 195–201.
5.
IsraelB.F., KenneyS.C.EBV lytic infection. In RobertsonE.S.. Epstein–Barr virus. Norfolk: Caister Academic Press2005; pp. 571–611.
6.
MillerG., El-GuindyA., CountrymanJ., YeJ., GradovilleL.Lytic cycle switches of oncogenic human gammaherpesviruses.Adv Cancer Res2007; 97: 81–109.
7.
BalfourH.H.Jr., HokansonK.M., SchachererR.M.A virologic pilot study of valacyclovir in infectious mononucleosis.J Clin Virol2007; 39: 16–21.
8.
FongI.W., HoJ., ToyC., LoB., FongM.W.Value of long-term administration of acyclovir and similar agents for protecting against AIDS-related lymphoma: case-control and historical cohort studies.Clin Infect Dis2000; 30: 757–761.
SchmidtW., AnagnostopoulosI., ScherublH.Virostatic therapy for advanced lymphoproliferation associated with the Epstein–Barr virus in an HIV-infected patient.N Engl J Med2000; 342: 440–441.
11.
SchneiderU., RuhnkeM., DelecluseH.J., SteinH., HuhnD.Regression of Epstein–Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet.Ann Hematol2000; 79: 214–216.
12.
FengP., RenE.C., LiuD., ChanS.H., HuH.Expression of Epstein–Barr virus lytic gene BRLF1 in nasopharyngeal carcinoma: potential use in diagnosis.J Gen Virol2000; 81: 2417–2423.
13.
GermiR., MorandP., Brengel-PesceK.Quantification of gp350/220 Epstein–Barr virus (EBV) mRNA by real-time reverse transcription-PCR in EBV-associated diseases.Clin Chem2004; 50: 1814–1817.
14.
HopwoodP.A., BrooksL., ParrattR.Persistent Epstein–Barr virus infection: unrestricted latent and lytic viral gene expression in healthy immunosuppressed transplant recipients.Transplantation2002; 74: 194–202.
15.
Martel-RenoirD., GrunewaldV., TouitouR., SchwaabG., JoabI.Qualitative analysis of the expression of Epstein– Barr virus lytic genes in nasopharyngeal carcinoma biopsies.J Gen Virol1995; 76: 1401–1408.
16.
ReaD., FourcadeC., LeblondV.Patterns of Epstein–Barr virus latent and replicative gene expression in Epstein–Barr virus B cell lymphoproliferative disorders after organ transplantation.Transplantation1994; 58: 317–324.
17.
AltmannM., HammerschmidtW.Epstein–Barr virus provides a new paradigm: a requirement for the immediate inhibition of apoptosis.PLoS Biol2005; 3: e404.
18.
HongG.K., GulleyM.L., FengW.H.Epstein–Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.J Virol2005; 79: 13993–14003.
19.
HongG.K., KumarP., WangL.Epstein–Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines.J Virol2005; 79: 13984–13992.
20.
GreenspanD., GreenspanJ.S.Oral lesions of HIV infections: features and therapy.AIDS Clin Rev1990; 81–93.
21.
AdhikaryD., BehrendsU., BoerschmannH.Immunodominance of lytic cycle antigens in Epstein–Barr virus-specific CD4+ T cell preparations for therapy.PLoS One2007; 2: e583.
22.
SavoldoB., GossJ.A., HammerM.M.Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs).Blood2006; 108: 2942–2949.
23.
PetosaC., MorandP., BaudinF., MoulinM., ArteroJ.B., MullerC. W.. Structural basis of lytic cycle activation by the Epstein–Barr virus ZEBRA protein.Mol Cell2006; 21: 565–572.
BuissonM., HernandezJ.F., LascouxD.The crystal structure of the Epstein–Barr virus protease shows rearrangement of the processed C terminus.J Mol Biol2002; 324: 89–103.
26.
DonaghyG., JuppR.Characterization of the Epstein– Barr virus proteinase and comparison with the human cytomegalovirus proteinase.J Virol1995; 69: 1265–1270.
27.
BuissonM., RivailL., HernandezJ.F.Kinetics, inhibition and oligomerization of Epstein–Barr virus protease.FEBS Lett2006; 580: 6570–6578.
28.
BuissonM., ValetteE., HernandezJ.F.Functional determinants of the Epstein–Barr virus protease.J Mol Biol2001; 311: 217–228.
29.
WaxmanL., DarkeP.L.The herpesvirus proteases as targets for antiviral chemotherapy.Antivir Chem Chemother2000; 11: 1–22.
30.
JohannsenE., LuftigM., ChaseM.R.Proteins of purifed Epstein–Barr virus.Proc Natl Acad Sci U S A2004; 101: 16286–16291.
31.
HongM., MuraiY., KutsunaT.Suppression of Epstein–Barr nuclear antigen 1 (EBNA1) by RNA interference inhibits proliferation of EBV-positive Burkitt's lymphoma cells.J Cancer Res Clin Oncol2006; 132: 1–8.
32.
YinQ., FlemingtonE.K.siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells.Virology2006; 346: 385–393.
33.
LiX.P., LiG., PengY., KungH.F., LinM.C.Suppression of Epstein–Barr virus-encoded latent membrane protein-1 by RNA interference inhibits the metaststic potential of nasopharyngeal carcinoma cells.Biochem Biophys Res Commun2004; 315: 212–218.
34.
LiX., LiuX., LiC.Y.Recombinant adeno-associated virus mediated RNA interfrence inhibits metastasis of nasopharyngeal cancer cells in vivo and in vitro by suppression of Epstein–Barr virus encoded LMP-1.Int J Oncol2006; 29: 595–603.
35.
MeiY.P., ZhouJ.M., WangY.Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells.Cell Cycle2007; 6: 1379–1385.
36.
MeiY.P., ZhuX.F., ZhouJ.M., HuangH., DengR., ZengY.X.siRNA targeting LMP1-induced apoptosis in EBV-positive lymphoma cells is associated with inhibition of telomerase activity and expression.Cancer Lett2006; 232: 189–198.
37.
ChangY., ChangS.S., LeeH.H., DoongS.L., TakadaK., TsaiC.H.Inhibition of the Epstein–Barr virus lytic cycle by Zta-targeted RNA interference.J Gen Virol2004; 85: 1371–1379.
38.
GershburgE., RaffaS., TorrisiM.R., PaganoJ.S.Epstein–Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus.J Virol2007; 81: 5407–5412.
39.
DelecluseH-J, HilsendegenT., PichD., ZeidlerR., HammerschmidtW.Propagation and recovery of intact, infectious Epstein–Barr virus from prokaryotic to human cells.Proc Natl Acad Sci U S A1998; 95: 8245–8250.
40.
FronhoffsS., TotzkeG., StierS.A method for the rapid construction of cRNA standard curves in quantitative realtime reverse transcription polymerase chain reaction.Mol Cell Probes2002; 16: 99–110.
41.
Brengel-PesceK., MorandP., SchmuckA.Routine use of real-time quantitative PCR for laboratory diagnosis of Epstein–Barr virus infections.J Med Virol2002; 66: 360–369.
42.
DelecluseH-J, HammerschmidtW.The genetic approach to the Epstein–Barr virus: from basic virology to gene therapy.Mol Pathol2000; 53: 270–279.
43.
StevensonA.J., MorrisonE.E., ChaudhariR., YangC.C., MeredithD.M.Processing and intracellular localization of the herpes simplex virus type 1 proteinase.J Gen Virol1997; 78: 671–675.
44.
PyrcK., BoschB.J., BerkhoutB.Inhibition of human coronavirus NL63 infection at early stages of the replication cycle.Antimicrob Agents Chemother2006; 50: 2000–2008.
45.
WesterhoutE.M., OomsM., VinkM., DasA.T., BerkhoutB.HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome.Nucleic Acids Res2005; 33: 796–804.
46.
ZhengB.J., GuanY., TangQ.Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus.Antivir Ther2004; 9: 365–374.
